Trial
NCT03329885
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
BMS-986251
Why stopped
Adverse change in the risk/benefit
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-21